The Impact of PTAB Proceedings on Bio/Pharma Litigation and Strategy

Annual PTAB Webinar Series: The Impact of PTAB Proceedings on Bio/Pharma Litigation and Strategy

While AIA proceedings are a popular mechanism to challenge patents, their use and influence in the bio/pharma space has been different than in other technology areas. As these proceedings have matured and evolved over the years, their influence in the bio/pharma space has evolved as well. Join us as we discuss the following topics:

• A review of how bio/pharma patents have fared before the PTAB;
• An analysis of how PTAB proceedings are impacting ANDA and biosimilar litigations;
• A discussion of how recent precedential PTAB decisions are impacting PTAB invalidity proceedings in the bio/pharma space;
• A discussion of expectations and potential strategies going forward.

Earn up to 1.0 Professional CLE for NJ/NY/PA

Speaker

Alison J. Baldwin has 20 years of experience in pharmaceutical and agricultural matters, Alison Baldwin is uniquely equipped to advance your most complex intellectual property goals. Whether you Eat it, Drink it, Wear it, Smoke it or Drive it, Alison’s extensive background in biotechnology and plant science brings a vital perspective to your project. [Read More]

Moderator Matthew Hartman, Counsel, Akin Gump, NJIPLA Chair, PTAB Committee

Thank You To Our Sponsor

GoToWebinar Note: Once you register, you will receive a GoToWebinar confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.